
Opinion|Videos|March 14, 2025
How Bispecific Antibodies Are Reshaping Cancer Care
Experts discuss how the availability of bispecific therapies has influenced treatment paradigms in oncology and how bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How has the availability of bispecific therapies influenced treatment paradigms in oncology?
- How do bispecifics fit into current treatment algorithms for hematologic malignancies and solid tumors?
Advertisement
Related to this article

Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.

In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.

The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Advertisement
Advertisement


